April 2023

A study shows that an enzyme deletion in viruses used in cancer immunotherapy improves effectiveness

Now a work co-led by the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona (UB) together with the LMU in Munich has studied the antitumor effect of an enzyme elimination in viruses of the poxvirus family

The Generalitat recognizes 32 IDIBELL groups as Consolidated or Emerging Research Groups

The Agency for the Management of University and Research Grants (AGAUR) has published this week the final resolution of the call for grants to support the activities of research groups from universities, centers and foundations. In this year’s call, 32 IDIBELL groups have been recognized as Consolidated or Emerging Research Groups, of which 19 will receive funding.

Researchers generate a stem cell-based model to study an ultra-rare disease that causes childhood parkinsonism

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), the Sant Joan de Déu Research Institute (IRSJD), Sant Pau Research Institute (IIB Sant Pau) and the UB generated the first model of this disease that reproduce patients’ characteristics and response to treatment.

Scroll to Top